# Prospective Multicenter Study Evaluating Myval TAVR Safety and Effectiveness in High-risk Severe AR

Study · id `cardio:ct-nct07751965` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07751965](<https://clinicaltrials.gov/study/NCT07751965>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07751965

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 164 participants.

## Technical summary

Registry record NCT07751965. Allocation not applicable; no masking; primary purpose treatment. Start 2026-10-30 (anticipated); primary completion 2027-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 164 participants (planned count; ClinicalTrials.gov record NCT07751965, source copy `cardio:ctgov-nct07751965-2026-08-07`, retrieved 2026-10-26)
- Planned start: 2026-10-30 (anticipated) (ClinicalTrials.gov record NCT07751965, source copy `cardio:ctgov-nct07751965-2026-08-07`, retrieved 2026-10-26)
- Primary completion: 2027-12-30 (anticipated) (ClinicalTrials.gov record NCT07751965, source copy `cardio:ctgov-nct07751965-2026-08-07`, retrieved 2026-10-26)
- Completion: 2032-03-30 (anticipated) (ClinicalTrials.gov record NCT07751965, source copy `cardio:ctgov-nct07751965-2026-08-07`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07751965-2026-08-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Prospective Multicenter Study Evaluating Myval TAVR Safety and Effectiveness in High-risk Severe AR
- Acronym: MARVELTAVI
- Condition: Aortic Regurgitation
- Condition: Aortic Disease
- Condition: Calcified Aortic Valve
- Intervention (Device): Myval THV series
- Lead sponsor: Ceric Sàrl
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic regurgitation (`cardio:aortic-regurgitation`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Ceric Sàrl (`cardio:org-ceric-sarl`)

## Provenance

Content hash: 930c4cb74c9572b357bbdebf22876ba0926e822f5e8168fb0f449593fb3c23cb
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
